The use of intraventricular vancomycin in the treatment of CSF shunt-associated ventriculitis
Related Experiment Videos
Abstract:
Ten cases of shunt-associated ventriculitis treated with intraventricular vancomycin are described. Eight were cured of their infection, one of these without shunt removal, though this failed in another instance. There were no toxic or untoward effects except in one case, where intravenous administration of vancomycin produced a histamine-like reaction. Intraventricular vancomycin, preferably combined with oral rifampicin, should be considered in cases of intractable or problematic shunt-associated ventriculitis due to Gram-positive organisms.
Insights
Intraventricular vancomycin effectively treated eight of ten cases of shunt-associated ventriculitis. This approach, especially with rifampicin, offers a viable option for difficult Gram-positive infections, with minimal toxicity.
Area of Science:
- Neuroscience
- Infectious Diseases
- Pharmacology
Background:
- Shunt-associated ventriculitis is a serious complication of cerebrospinal fluid (CSF) shunting procedures.
- Gram-positive organisms are common causative agents, often requiring targeted antibiotic therapy.
- Intractable or recurrent infections pose significant treatment challenges.
Purpose of the Study:
- To evaluate the efficacy and safety of intraventricular vancomycin for treating shunt-associated ventriculitis.
- To assess the role of intraventricular vancomycin, with or without shunt removal, in achieving infection cure.
- To determine the potential benefits of combining intraventricular vancomycin with oral rifampicin.
Main Methods:
- Retrospective case series describing ten patients with shunt-associated ventriculitis.
- Treatment involved intraventricular vancomycin administration.
- Adjunctive therapies, including oral rifampicin and shunt management, were noted.
Main Results:
- Eight out of ten patients achieved a cure of their ventriculitis.
- One patient was cured without requiring shunt removal.
- Adverse effects were minimal, with one instance of a histamine-like reaction to intravenous vancomycin.
Conclusions:
- Intraventricular vancomycin demonstrates significant efficacy in treating shunt-associated ventriculitis caused by Gram-positive organisms.
- Combination therapy with oral rifampicin may enhance treatment outcomes for challenging cases.
- This treatment modality should be considered for intractable or problematic shunt infections, offering a potentially less invasive option than complete shunt revision in select cases.